Voyager Therapeutics’ (VYGR) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note published on Wednesday morning,Benzinga reports.

Other analysts have also recently issued reports about the company. Citigroup started coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Monday, March 3rd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Finally, StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $14.86.

Voyager Therapeutics Price Performance

NASDAQ VYGR opened at $3.90 on Wednesday. The stock has a market capitalization of $213.04 million, a PE ratio of 5.49 and a beta of 0.99. Voyager Therapeutics has a 1 year low of $3.56 and a 1 year high of $10.66. The business’s 50-day moving average is $4.88 and its 200 day moving average is $5.85.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The business had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the previous year, the business earned $1.25 earnings per share. As a group, equities research analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Activity

In other news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 10,778 shares of company stock worth $58,548. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently made changes to their positions in VYGR. Empowered Funds LLC lifted its holdings in shares of Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after purchasing an additional 2,278 shares during the last quarter. Intech Investment Management LLC purchased a new position in Voyager Therapeutics in the 3rd quarter worth approximately $74,000. Massachusetts Financial Services Co. MA raised its holdings in Voyager Therapeutics by 19.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 171,856 shares of the company’s stock worth $1,005,000 after acquiring an additional 28,333 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Voyager Therapeutics by 2.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock worth $804,000 after acquiring an additional 3,473 shares during the last quarter. Finally, FMR LLC raised its holdings in Voyager Therapeutics by 26.9% in the 3rd quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after acquiring an additional 19,622 shares during the last quarter. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.